Miki Tateyama
Overview
Explore the profile of Miki Tateyama including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
132
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Komatsu Y, Yuki S, Sogabe S, Fukushima H, Iwanaga I, Kudo M, et al.
Oncology
. 2011 Jun;
80(1-2):70-5.
PMID: 21659785
Objectives: This phase II study was designed to evaluate the efficacy and safety of oral fluoropyrimidine S-1 plus irinotecan (IRIS regimen) in patients with previously untreated metastatic colorectal cancer. Methods:...
12.
Komatsu Y, Yuki S, Fuse N, Kato T, Miyagishima T, Kudo M, et al.
Adv Ther
. 2010 Jun;
27(7):483-92.
PMID: 20559897
Background: Irinotecan and S-1, an oral fluoropyrimidine composed of tegafur, gimeracil, and oteracil potassium, have demonstrated antitumor activity against advanced gastric cancer. We performed a phase 1/2 study to determine...
13.
Yuuki S, Komatsu Y, Fuse N, Kato T, Miyagishima T, Kudo M, et al.
Clin Drug Investig
. 2010 Mar;
30(4):243-9.
PMID: 20225907
Background: Combined therapy with irinotecan/fluorouracil/levoleucovorin (calcium levofolinate) [IFL] has lost its position as the standard regimen for metastatic colorectal cancer because its toxicity and effectiveness have become controversial. Objective: To...
14.
Komatsu Y, Yuki S, Tateyama M, Kudo M, Asaka M
Gan To Kagaku Ryoho
. 2006 Aug;
33 Suppl 1:131-4.
PMID: 16897988
We planned to conduct a phase II clinical study of combination therapy with CPT-11 and S-1. The antitumor effect was the primary endpoint, while the safety, progression-free survival time, and...
15.
Komatsu Y, Yuuki S, Fuse N, Takei M, Kato T, Miyagishima T, et al.
Jpn J Clin Oncol
. 2005 Feb;
35(2):88-9.
PMID: 15709093
We have previously reported on phase I/II studies of irinotecan plus S-1 therapy for advanced gastric cancer. Based on the safety and efficacy data that were obtained, this phase II...